Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics

Core Insights - Clearmind Medicine Inc. is advancing its mission to develop psychedelic-derived therapeutics by engaging a prominent government and political affairs consulting firm to navigate regulatory landscapes and promote acceptance among U.S. policymakers [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on discovering and developing novel psychedelic-derived therapeutics aimed at addressing major under-treated health issues, including alcohol use disorder [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property as opportunities arise [5] Industry Context - The pharmaceutical industry is increasingly recognizing the potential of psychedelics to treat conditions such as Post-Traumatic Stress Disorder (PTSD) and other mental health disorders, necessitating informed regulatory frameworks to facilitate the integration of these therapies into mainstream healthcare [2][3] - Clearmind's lead candidate, CMND-100, is currently undergoing Phase I/IIa clinical trials for alcohol use disorder at prestigious institutions, including Yale School of Medicine and Johns Hopkins University [3]